

Special Issue

Targeting STATs for Anti-cancer Therapy

Message from the Guest Editor

We are extremely pleased to offer a special issue focused on Targeting STATs for Anti-Cancer Therapy, for the journal *Cancers*. **Scope** - Publish high quality research articles targeting STAT signaling in the tumor and tumor microenvironment using innovative or incremental therapeutic approaches. Signal Transducers and Activators of Transcription (STATs) family members, particularly STAT3 and STAT5 are constitutively activated in many cancers and are thought to be ideal candidates for anti-cancer therapy. Several strategies have been explored to target the two oncogenes. Although some inhibitors showed profound antitumor activity in inhibiting the biological function of the oncogenes, however there are no clinical grade lead inhibitors. Research articles may include (but are not limited) to the following:

- Therapeutic inhibition of the STAT pathway in preclinical cancer models
- Identifying mechanism of action contributing to hyperactivation of the STAT molecules
- Clinical grade STAT inhibitors in clinical trials
- Identify dysregulation of key molecules influencing STAT molecule activation for efficient patient stratification to benefit from therapy

Guest Editor

Dr. Malabika Sen

UPMC Hillman Cancer Center, Pittsburgh, PA, USA

Deadline for manuscript submissions

closed (28 February 2023)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/116441

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)